The DOI matches its Crossref record; 337 of the 337 references it cites were found in a registry or an index.
PARP and PARG inhibitors in cancer treatment
Open accessAbstract
Oxidative and replication stress underlie genomic instability of cancer cells. Amplifying genomic instability through radiotherapy and chemotherapy has been a powerful but nonselective means of killing cancer cells. Precision medicine has revolutionized cancer therapy by putting forth the concept of selective targeting of cancer cells. Poly(ADP-ribose) polymerase (PARP) inhibitors represent a successful example of precision medicine as the first drugs targeting DNA damage response to have entered the clinic. PARP inhibitors act through synthetic lethality with mutations in DNA repair genes and were approved for the treatment of BRCA mutated ovarian and breast cancer. PARP inhibitors destabilize replication forks through PARP DNA entrapment and induce cell death through replication stress-induced mitotic catastrophe. Inhibitors of poly(ADP-ribose) glycohydrolase (PARG) exploit and exacerbate replication deficiencies of cancer cells and may complement PARP inhibitors in targeting a broad range of cancer types with different sources of genomic instability. Here I provide an overview of the molecular mechanisms and cellular consequences of PARP and PARG inhibition. I highlight clinical performance of four PARP inhibitors used in cancer therapy (olaparib, rucaparib, niraparib, and talazoparib) and discuss the predictive biomarkers of inhibitor sensitivity, mechanisms of resistance as well as the means of overcoming them through combination therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–337 of 337
Lips, E. H., Mulder, L., Oonk, A., van der Kolk, L. E., Hogervorst, F. B. L., Imholz, A. L. T., Wesseling, J., Rodenhuis, S., & Nederlof, P. M. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.144 · Cited by 231
Trapping Poly(ADP-Ribose) Polymerase
Shen, Y., Aoyagi-Scharber, M., & Wang, B. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.222448 · Cited by 230
Genome-wide transcriptome profiling of homologous recombination DNA repair
Peng, G., Chun-Jen Lin, C., Mo, W., Dai, H., Park, Y.-Y., Kim, S. M., Peng, Y., Mo, Q., Siwko, S., Hu, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms4361 · Cited by 229
Stewart, C. A., Tong, P., Cardnell, R. J., Sen, T., Li, L., Gay, C. M., Masrorpour, F., Fan, Y., Bara, R. O., Feng, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15338 · Cited by 227
Poly(ADP-ribose) catabolism in mammalian cells exposed to DNA-damaging agents
Alvarez-Gonzalez, R., & Althaus, F. R. (1989) · Mutation Research/DNA Repair · doi:10.1016/0921-8777(89)90012-8 · Cited by 224
Ronson, G. E., Piberger, A. L., Higgs, M. R., Olsen, A. L., Stewart, G. S., McHugh, P. J., Petermann, E., & Lakin, N. D. (2018) · Nature Communications · doi:10.1038/s41467-018-03159-2 · Cited by 221
DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells
He, Y. J., Meghani, K., Caron, M.-C., Yang, C., Ronato, D. A., Bian, J., Sharma, A., Moore, J., Niraj, J., Detappe, A., et al. (2018) · Nature · doi:10.1038/s41586-018-0670-5 · Cited by 219
Bryant, H. E. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl108 · Cited by 212
PARP inhibitor combination therapy
Dréan, A., Lord, C. J., & Ashworth, A. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.10.010 · Cited by 212
PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA
Sugimura, K., Takebayashi, S.-I., Taguchi, H., Takeda, S., & Okumura, K. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200806068 · Cited by 211
PARP inhibitors in ovarian cancer
Franzese, E., Centonze, S., Diana, A., Carlino, F., Guerrera, L. P., Di Napoli, M., De Vita, F., Pignata, S., Ciardiello, F., & Orditura, M. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.12.002 · Cited by 211
Linking abnormal mitosis to the acquisition of DNA damage
Ganem, N. J., & Pellman, D. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201210040 · Cited by 208
Muvarak, N. E., Chowdhury, K., Xia, L., Robert, C., Choi, E. Y., Cai, Y., Bellani, M., Zou, Y., Singh, Z. N., Duong, V. H., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.002 · Cited by 201
Christie, E. L., Fereday, S., Doig, K., Pattnaik, S., Dawson, S.-J., & Bowtell, D. D. L. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.4627 · Cited by 196
Transcriptional Roles of PARP1 in Cancer
Schiewer, M. J., & Knudsen, K. E. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0672 · Cited by 186
Godon, C., Cordelieres, F. P., Biard, D., Giocanti, N., Megnin-Chanet, F., Hall, J., & Favaudon, V. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn403 · Cited by 186
Structural Implications for Selective Targeting of PARPs
Steffen, J. D., Brody, J. R., Armen, R. S., & Pascal, J. M. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00301 · Cited by 182
BRCA1 haploinsufficiency for replication stress suppression in primary cells
Pathania, S., Bade, S., Le Guillou, M., Burke, K., Reed, R., Bowman-Colin, C., Su, Y., Ting, D. T., Polyak, K., Richardson, A. L., et al. (2014) · Nature Communications · doi:10.1038/ncomms6496 · Cited by 181
Dantzer, F., Nasheuer, H. P., Vonesch, J. L., de Murcia, G., & Murcia, J. M.-D. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.8.1891 · Cited by 178
Min, A., Im, S.-A., Kim, D. K., Song, S.-H., Kim, H.-J., Lee, K.-H., Kim, T.-Y., Han, S.-W., Oh, D.-Y., Kim, T.-Y., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0534-y · Cited by 177
The DNA Damaging Revolution: PARP Inhibitors and Beyond
Yap, T. A., Plummer, R., Azad, N. S., & Helleday, T. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238473 · Cited by 177
Maya-Mendoza, A., Ostrakova, J., Kosar, M., Hall, A., Duskova, P., Mistrik, M., Merchut-Maya, J. M., Hodny, Z., Bartkova, J., Christensen, C., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2014.11.001 · Cited by 176
Veeck, J., Ropero, S., Setien, F., Gonzalez-Suarez, E., Osorio, A., Benitez, J., Herman, J. G., & Esteller, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.1010 · Cited by 176
BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer
Karakashev, S., Zhu, H., Yokoyama, Y., Zhao, B., Fatkhutdinov, N., Kossenkov, A. V., Wilson, A. J., Simpkins, F., Speicher, D., Khabele, D., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.095 · Cited by 174
Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
Shroff, R. T., Hendifar, A., McWilliams, R. R., Geva, R., Epelbaum, R., Rolfe, L., Goble, S., Lin, K. K., Biankin, A. V., Giordano, H., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00316 · Cited by 174
Preserving replication fork integrity and competence via the homologous recombination pathway
Ait Saada, A., Lambert, S. A. E., & Carr, A. M. (2018) · DNA Repair · doi:10.1016/j.dnarep.2018.08.017 · Cited by 173
Pettitt, S. J., Rehman, F. L., Bajrami, I., Brough, R., Wallberg, F., Kozarewa, I., Fenwick, K., Assiotis, I., Chen, L., Campbell, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061520 · Cited by 172
PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors
Farrés, J., Llacuna, L., Martin-Caballero, J., Martínez, C., Lozano, J. J., Ampurdanés, C., López-Contreras, A. J., Florensa, L., Navarro, J., Ottina, E., et al. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.202 · Cited by 172
Wang, B., Chu, D., Feng, Y., Shen, Y., Aoyagi-Scharber, M., & Post, L. E. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01498 · Cited by 171
PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
Keung, M., Wu, Y., & Vadgama, J. V. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8040435 · Cited by 170
Nogales, V., Reinhold, W. C., Varma, S., Martinez-Cardus, A., Moutinho, C., Moran, S., Heyn, H., Sebio, A., Barnadas, A., Pommier, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6413 · Cited by 169
HELB Is a Feedback Inhibitor of DNA End Resection
Tkáč, J., Xu, G., Adhikary, H., Young, J. T. F., Gallo, D., Escribano‐Diaz, C., Krietsch, J., Orthwein, A., Munro, M., Sol, W., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2015.12.013 · Cited by 168
Barazas, M., Annunziato, S., Pettitt, S. J., de Krijger, I., Ghezraoui, H., Roobol, S. J., Lutz, C., Frankum, J. R., Song, F., Brough, R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.046 · Cited by 165
Hatakeyama, K., Nemoto, Y., Ueda, K., & Hayaishi, O. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)66802-4 · Cited by 164
Naipal, K. A. T., Verkaik, N. S., Ameziane, N., van Deurzen, C. H. M., ter Brugge, P., Meijers, M., Sieuwerts, A. M., Martens, J. W., O'Connor, M. J., Vrieling, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0571 · Cited by 162
Drew, Y., Ledermann, J., Hall, G., Rea, D., Glasspool, R., Highley, M., Jayson, G., Sludden, J., Murray, J., Jamieson, D., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.41 · Cited by 162
RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer
Liu, Y., Burness, M. L., Martin-Trevino, R., Guy, J., Bai, S., Harouaka, R., Brooks, M. D., Shang, L., Fox, A., Luther, T. K., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1348 · Cited by 162
Pillay, N., Tighe, A., Nelson, L., Littler, S., Coulson‐Gilmer, C., Bah, N. K., Golder, A., Bakker, B., Spierings, D. C. J., James, D. I., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.004 · Cited by 161
Lowery, M. A., Kelsen, D. P., Capanu, M., Smith, S., Lee, J. W., Stadler, Z. K., Moore, M. J., Kindler, H. L., Golan, T., Segal, A., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.11.004 · Cited by 159
Lallo, A., Frese, K. K., Morrow, C. J., Sloane, R. A. S., Gulati, S., Schenk, M. W., Trapani, F., Simms, N., Galvin, M., Brown, S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2805 · Cited by 157
James, D. I., Smith, K. M., Jordan, A. M., Fairweather, E. E., Griffiths, L. A., Hamilton, N. S., Hitchin, J. R., Hutton, C. P., Jones, S. D., Kelly, P. J., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00609 · Cited by 155
Lheureux, S., Lai, Z., Dougherty, B. A., Runswick, S. K., Hodgson, D., Timms, K. M., Lanchbury, J. S. S., Kaye, S. B., Gourley, C., Bowtell, D. D. L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2615 · Cited by 155
Barkauskaite, E., Brassington, A., Tan, E. S., Warwicker, J., Dunstan, M. S., Piñero, B. B., Lafite, P., Ahel, M., Mitchison, T. J., Ahel, I., et al. (2013) · Nature Communications · doi:10.1038/ncomms3164 · Cited by 153
PARG is recruited to DNA damage sites through poly(ADP-ribose)- and PCNA-dependent mechanisms
Mortusewicz, O., Fouquerel, E., Amé, J., Leonhardt, H., & Schreiber, V. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr099 · Cited by 151
Carey, J. P. W., Karakaş, C., Bui, T. N., Chen, X., Vijayaraghavan, S., Zhao, Y., Wang, J., Mikule, K. W., Litton, J. K., Hunt, K. K., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1494 · Cited by 151
Mo, W., Liu, Q., Lin, C. C.-J., Dai, H., Peng, Y., Liang, Y., Peng, G., Meric‐Bernstam, F., Mills, G. B., Li, K., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1772 · Cited by 149
Wielckens, K., Schmidt, A., George, E., Bredehorst, R., & Hilz, H. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)33596-8 · Cited by 148
BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1
Drost, R., Dhillon, K. K., van der Gulden, H. M. L., van der Heijden, I., Brandsma, I., Cruz, C., Chondronasiou, D., Castroviejo‐Bermejo, M., Boon, U., Schut, E., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci70196 · Cited by 146
Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death
Houl, J. H., Ye, Z., Brosey, C. A., Balapiti-Modarage, L. P. F., Namjoshi, S., Bacolla, A., Laverty, D. J., Walker, B. L., Pourfarjam, Y., Warden, L. S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13508-4 · Cited by 145
Haynes, B. M., Murai, J., & Lee, J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.09.003 · Cited by 144
Targeting DNA damage repair in small cell lung cancer and the biomarker landscape
Sen, T., Gay, C. M., & Byers, L. A. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.02.03 · Cited by 142
Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function
Feng, F. Y.-C., Bono, J. S. D., Rubin, M. A., & Knudsen, K. E. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.04.016 · Cited by 141
Koch, S. S. C., Thoresen, L. H., Tikhe, J. G., Maegley, K. A., Almassy, R. J., Li, J., Yu, X., Zook, S. E., Kumpf, R. A., Zhang, C., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020259n · Cited by 141
Min, W., Bruhn, C., Grigaravičius, P., Zhou, Z., Li, F., Krüger, A., Siddeek, B., Greulich, K., Popp, O., Meisezahl, C., et al. (2013) · Nature Communications · doi:10.1038/ncomms3993 · Cited by 141
Turner, N. C., Telli, M. L., Rugo, H. S., Mailliez, A., Ettl, J., Grischke, E., Mina, L. A., Balmañà, J., Fasching, P. A., Hurvitz, S. A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1891 · Cited by 141
Radiation-induced mitotic catastrophe in PARG-deficient cells
Amé, J., Fouquerel, E., Gauthier, L., Biard, D. S. F., Boussin, F. D., Dantzer, F., de MURCIA, G., & Schreiber, V. (2009) · Journal of Cell Science · doi:10.1242/jcs.039115 · Cited by 139
Domagała, P., Huzarski, T., Lubiński, J., Gugała, K., & Domagała, W. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1441-2 · Cited by 137
Parsels, L. A., Karnak, D. M., Parsels, J. D., Zhang, Q., Vélez-Padilla, J., Reichert, Z. R., Wahl, D. R., Maybaum, J., O’Connor, M. J., Lawrence, T. S., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0455 · Cited by 137
Yang, G., Liu, C., Chen, S.-H., Kassab, M. A., Hoff, J. D., Walter, N. G., & Yu, X. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky088 · Cited by 137
PTIP associates with Artemis to dictate DNA repair pathway choicePreprint
Wang, J., Asaithamby, A., Löbrich, M., Li, Y., Chen, D. J., Chen, J., & Gong, Z. (2014) · Genes & Development · doi:10.1101/gad.252478.114 · Cited by 134
Latest clinical evidence and further development of PARP inhibitors in ovarian cancer
Mirza, M. R., Pignata, S., & Ledermann, J. A. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy174 · Cited by 134
Michelena, J., Lezaja, A., Teloni, F., Schmid, T., Imhof, R., & Altmeyer, M. (2018) · Nature Communications · doi:10.1038/s41467-018-05031-9 · Cited by 131
Henneman, L., van Miltenburg, M. H., Michalak, E. M., Braumuller, T. M., Jaspers, J. E., Drenth, A. P., de Korte‐Grimmerink, R., Gogola, E., Szuhai, K., Schlicker, A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500223112 · Cited by 129
YAMAGUCHI, H., Du, Y., Nakai, K., Ding, M., Chang, S. H., Hsu, J. L., Yao, J., Wei, Y., Nie, L., Jiao, S., et al. (2017) · Oncogene · doi:10.1038/onc.2017.311 · Cited by 129
BRCA1 promoter methylation predicts adverse ovarian cancer prognosis
Chiang, J. W., Karlan, B. Y., Cass, L., & Baldwin, R. L. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.10.034 · Cited by 125
Clark, J. B., Ferris, G., & Pinder, S. (1971) · Biochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis · doi:10.1016/0005-2787(71)90012-8 · Cited by 124
PARP Trapping Beyond Homologous Recombination and Platinum Sensitivity in Cancers
Murai, J., & Pommier, Y. G. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055914 · Cited by 119
Gallagher, D. J., Konner, J. A., Bell-McGuinn, K. M., Bhatia, J., Sabbatini, P. J., Aghajanian, C. A., Offit, K., Barakat, R. R., Spriggs, D. R., & Kauff, N. D. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq577 · Cited by 118
Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors
Philip, C., Laskov, I., Beauchamp, M.-C., Marques, M., Amin, O., Bitharas, J., Kessous, R., Kogan, L., Baloch, T., Gotlieb, W. H., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3639-0 · Cited by 117
Simbulan-Rosenthal, C. M., Rosenthal, D. S., Luo, R., Samara, R. N., Espinoza, L. A., Hassa, P. O., Hottiger, M. O., & Smulson, M. E. (2003) · Oncogene · doi:10.1038/sj.onc.1206897 · Cited by 115
Purification and properties of poly(adenosine diphosphate ribose) synthetase.
Okayama, H., Edson, C. M., Fukushima, M., Ueda, K., & Hayaishi, O. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)66926-7 · Cited by 111
Schoonen, P. M., Talens, F., Stok, C., Gogola, E., Heijink, A. M., Bouwman, P., Foijer, F., Tarsounas, M., Blatter, S., Jonkers, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms15981 · Cited by 108
Structure and mechanism of a canonical poly(ADP-ribose) glycohydrolase
Dunstan, M. S., Barkauskaite, E., Lafite, P., Knezevic, C. E., Brassington, A., Ahel, M., Hergenrother, P. J., Leys, D., & Ahel, I. (2012) · Nature Communications · doi:10.1038/ncomms1889 · Cited by 105
Postel-Vinay, S. C., Bajrami, I., Friboulet, L., Elliott, R. J. R., Fontebasso, Y., Dorvault, N., Olaussen, K. A., André, F., Soria, J., Lord, C. J., et al. (2013) · Oncogene · doi:10.1038/onc.2013.311 · Cited by 105
Wang, D., Li, C., Zhang, Y., Wang, M., Jiang, N., Lin, X., Li, T., Roberts, T. M., Zhao, J. J., Cheng, H.-L. M., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.07.092 · Cited by 105
Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets
Knezevic, C. E., Wright, G. M., Rix, L. L. R., Kim, W., Kuenzi, B. M., Luo, Y., Watters, J. M., Koomen, J. M., Haura, E. B., Monteiro, Á. N. A., et al. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.10.011 · Cited by 105
Chen, S.-H., & Yu, X. (2019) · Science Advances · doi:10.1126/sciadv.aav4340 · Cited by 105
Gallotannin Inhibits the Expression of Chemokines and Inflammatory Cytokines in A549 Cells
Erdélyi, K., Kiss, A., Bakondi, E., Bai, P., Szabó, C., Gergely, P., Erdődi, F., & Virág, L. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.012518 · Cited by 104
Colicchia, V., Petroni, M., Guarguaglini, G., Sardina, F., Roncero, M. S., Carbonari, M., Ricci, B., Heil, C., Capalbo, C., Belardinilli, F., et al. (2017) · Oncogene · doi:10.1038/onc.2017.40 · Cited by 104
Expanding functions of ADP-ribosylation in the maintenance of genome integrity
Martin-Hernandez, K., Rodríguez-Vargas, J. M., Schreiber, V., & Dantzer, F. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.09.009 · Cited by 102
Synergistic Loss of Prostate Cancer Cell Viability by Coinhibition of HDAC and PARP
Chao, O. S., & Goodman, O. B. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0173 · Cited by 100
Gravells, P., Grant, E. K., Smith, K. M., James, D. I., & Bryant, H. E. (2017) · DNA repair · doi:10.1016/j.dnarep.2017.02.010 · Cited by 97
Simbulan-Rosenthal, C. M., Rosenthal, D. S., Boulares, A. H., Hickey, R. J., Malkas, L. H., Coll, J. M., & Smulson, M. E. (1998) · Biochemistry · doi:10.1021/bi9731089 · Cited by 96
Illuzzi, G., Fouquerel, E., Amé, J., Noll, A., Rehmet, K., Nasheuer, H., Dantzer, F., & Schreiber, V. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku505 · Cited by 96
PARP Inhibitors as P-glyoprotein Substrates
Lawlor, D., Martin, P., Busschots, S., Thery, J., O’Leary, J. J., Hennessy, B. T., & Stordal, B. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23952 · Cited by 96
Inhibition of poly(ADP-ribose) glycohydrolase (PARG) specifically kills BRCA2-deficient tumor cells
Fathers, C., Drayton, R. M., Solovieva, S. E., & Bryant, H. E. (2012) · Cell Cycle · doi:10.4161/cc.11.5.19482 · Cited by 94
Nikkilä, J., Kumar, R., Campbell, J., Brandsma, I., Pemberton, H. N., Wållberg, F., Nagy, K., Scheer, I., Vértessy, B. G., Serebrenik, A. A., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.133 · Cited by 94
Tang, S.-W., Thomas, A., Murai, J., Trepel, J. B., Bates, S. E., Rajapakse, V. N., & Pommier, Y. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0443 · Cited by 94
Parrish, K. E., Cen, L., Murray, J., Calligaris, D., Kizilbash, S. H., Mittapalli, R. K., Carlson, B. L., Schroeder, M. A., Sludden, J., Boddy, A. V., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0553 · Cited by 93
Increased oxidative stress mediates the antitumor effect of PARP inhibition in ovarian cancer
Hou, D., Liu, Z., Xu, X., Liu, Q., Zhang, X., Kong, B., Wei, J., Gong, Y., & Shao, C. (2018) · Redox Biology · doi:10.1016/j.redox.2018.03.016 · Cited by 93
Lheureux, S., Bruce, J. P., Burnier, J. V., Karakasis, K., Shaw, P. A., Clarke, B. A., Yang, S. Y. C., Quevedo, R., Li, T., Dowar, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3677 · Cited by 92
Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts
Laird, J. H., Lok, B. H., Ma, J., Bell, A., de Stanchina, E., Poirier, J. T., & Rudin, C. M. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0401 · Cited by 85
Nowsheen, S., Cooper, T. S., Bonner, J. A., LoBuglio, A. F., & Yang, E. S.-H. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1287 · Cited by 84
Synthetic Lethality of Cohesins with PARPs and Replication Fork Mediators
McLellan, J. L., O’Neil, N. J., Barrett, I. J., Ferree, E. J., van Pel, D. M., Ushey, K., Sipahimalani, P., Bryan, J., Rose, A. M., & Hieter, P. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002574 · Cited by 83
Pishvaian, M. J., Biankin, A. V., Bailey, P. J., Chang, D. K.-F., Laheru, D. A., Wolfgang, C. L., & Brody, J. R. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.40 · Cited by 80
The evolving landscape of predictive biomarkers of response to PARP inhibitors
Thomas, A., Murai, J., & Pommier, Y. G. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120388 · Cited by 78
Marzio, A., Puccini, J., Kwon, Y., Maverakis, N., Arbini, A., Sung, P., Bar‐Sagi, D., & Pagano, M. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.11.003 · Cited by 74
Chand, S. N., Zarei, M., Schiewer, M. J., Kamath, A. R., Romeo, C., Lal, S., Cozzitorto, J. A., Nevler, A., Scolaro, L. M., Londin, E. R., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2704 · Cited by 73
Meghani, K. A., Fuchs, W., Detappe, A., Drané, P., Gogola, E., Rottenberg, S., Jonkers, J., Matulonis, U. A., Swisher, E. M., Konstantinopoulos, P. A., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.038 · Cited by 73
The influence of BRCA2 mutation on localized prostate cancer
Taylor, R. A., Fraser, M. E., Rebello, R. J., Boutros, P. C., Murphy, D. G., Bristow, R. G., & Risbridger, G. P. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0164-8 · Cited by 73
Shirai, H., Poetsch, A. R., Gunji, A., Maeda, D., Fujimori, H., Fujihara, H., Yoshida, T., Ogino, H., & Masutani, M. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.133 · Cited by 72
Mutational game changer: Chromothripsis and its emerging relevance to cancer
Luijten, M., Lee, J. X. T., & Crasta, K. (2018) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2018.06.004 · Cited by 72
Resistance to PARP Inhibitors: Lessons from Preclinical Models of BRCA-Associated Cancer
Gogola, E., Rottenberg, S., & Jonkers, J. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050232 · Cited by 71
The PIN domain of EXO1 recognizes poly(ADP-ribose) in DNA damage response
Zhang, F., Shi, J., Chen, S.-H., Bian, C., & Yu, X. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv939 · Cited by 70
Bernards, S. S., Pennington, K. P., Harrell, M. I., Agnew, K. J., Garcia, R. L., Norquist, B. M., & Swisher, E. M. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.12.004 · Cited by 70
Poly(ADP-Ribose) Mediates the BRCA2-Dependent Early DNA Damage Response
Zhang, F., Shi, J., Bian, C., & Yu, X. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.040 · Cited by 69
Kim, I., Kiefer, J. R., Ho, C. M. W., Stegeman, R. A., Classen, S., Tainer, J. A., & Ellenberger, T. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2305 · Cited by 68
Perspectives on PARPs in S Phase
Hanzlíková, H., & Caldecott, K. W. (2019) · Trends in Genetics · doi:10.1016/j.tig.2019.03.008 · Cited by 68
PARP-1 Expression is Increased in Colon Adenoma and Carcinoma and Correlates with OGG1
Dziaman, T., Ludwiczak, H., Cieśla, J., Banaszkiewicz, Z., Winczura, A., Chmielarczyk, M., Wisniewska, E., Marszałek, A., Tudek, B., & Oliński, R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115558 · Cited by 67
Chaudhuri, A. R., Ahuja, A. K., Herrador, R., & Lopes, M. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01077-14 · Cited by 67
NADP+ is an endogenous PARP inhibitor in DNA damage response and tumor suppression
Bian, C., Zhang, C., Luo, T., Vyas, A., Chen, S.-H., Liu, C., Kassab, M. A., Yang, Y., Kong, M., & Yu, X. (2019) · Nature Communications · doi:10.1038/s41467-019-08530-5 · Cited by 67
PARP‐1 regulates DNA repair factor availability
Schiewer, M. J., Mandigo, A. C., Gordon, N., Huang, F., Gaur, S., de Leeuw, R., Zhao, S. G., Evans, J. R., Han, S., Parsons, T., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708816 · Cited by 65
McGrail, D. J., Lin, C. C.-J., Garnett, J., Liu, Q., Mo, W., Dai, H., Lu, Y., Yu, Q., Ju, Z., Yin, J., et al. (2017) · npj Systems Biology and Applications · doi:10.1038/s41540-017-0011-6 · Cited by 64
Gravells, P., Neale, J., Grant, E. K., Nathubhai, A., Smith, K. M., James, D. I., & Bryant, H. E. (2017) · DNA repair · doi:10.1016/j.dnarep.2017.11.004 · Cited by 64
Lin, X., Chen, D., Zhang, C., Zhang, X., Li, Z., Dong, B., Gao, J., & Shen, L. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0790-7 · Cited by 62
Mitotic functions of poly(ADP-ribose) polymerases
Slade, D. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.03.028 · Cited by 59
Self-citationRein, I. D., Landsverk, K. S., Micci, F., Patzke, S., & Stokke, T. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1085137 · Cited by 58
Selective Small Molecule Inhibition of Poly(ADP-Ribose) Glycohydrolase (PARG)
Finch, K. E., Knezevic, C. E., Nottbohm, A. C., Partlow, K. C., & Hergenrother, P. J. (2012) · ACS Chemical Biology · doi:10.1021/cb200506t · Cited by 58
Falsig, J., Christiansen, S. H., Feuerhahn, S., Bürkle, A., Oei, S. L., Keil, C., & Leist, M. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.06.042 · Cited by 58
Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors
Barazas, M., Gasparini, A., Huang, Y., Küçükosmanoğlu, A., Annunziato, S., Bouwman, P., Sol, W., Kersbergen, A. J., Proost, N., de Korte‐Grimmerink, R., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-2077 · Cited by 58
Matulonis, U. A., & Monk, B. J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw697 · Cited by 57
AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations
Meng, X., Bi, J., Li, Y., Yang, S., Zhang, Y., Li, M., Liu, H., Li, Y., McDonald, M. E., Thiel, K. W., et al. (2018) · Cancers · doi:10.3390/cancers10050149 · Cited by 57
Tumor suppressive effect of PARP1 and FOXO3A in gastric cancers and its clinical implications
Park, S., Jang, K. Y., Kim, M. J., Yoon, S., Jo, Y., Kwon, S. M., Kim, K. M., Kwon, K. S., Kim, C. Y., & Woo, H. G. (2015) · Oncotarget · doi:10.18632/oncotarget.6264 · Cited by 54
Shah, M. M., Dobbin, Z. C., Nowsheen, S., Wielgos, M. E., Katre, A. A., Alvarez, R. D., Konstantinopoulos, P. A., Yang, E. S.-H., & Landen, C. N. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.05.009 · Cited by 53
Poly (ADP-ribose) polymerase 1 protein expression in normal and neoplastic prostatic tissue
Salemi, M., Galia, A., Fraggetta, F., CORTE, C. L., Pepe, P., Vignera, S. L., Improta, G., Bosco, P., & Calogero, A. E. (2013) · European Journal of Histochemistry · doi:10.4081/ejh.2013.e13 · Cited by 52
A novel non-canonical PIP-box mediates PARG interaction with PCNA
Kaufmann, T., Grishkovskaya, I., Polyansky, A. A., Kostrhon, S., Kukolj, E., Olek, K., Herbert, S., Beltzung, E., Mechtler, K., Peterbauer, T., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx604 · Cited by 52
Self-citationGenome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivity
Fang, P., Souza, C. D., Minn, K. T., & CHIEN, J. R. (2019) · Communications Biology · doi:10.1038/s42003-019-0580-6 · Cited by 52
Majuelos‐Melguizo, J., Rodríguez, M. I., López-Jiménez, L., Rodríguez-Vargas, J. M., Martí, J. M., Serrano, S., Gavard, J., de Almodóvar, J. M. R., & Oliver, F. J. (2014) · Oncotarget · doi:10.18632/oncotarget.2993 · Cited by 44
Giovannini, S., Weller, M.-C., Repmann, S., Moch, H., & Jiricny, J. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz624 · Cited by 40
DNA replication and poly(ADP-ribosyl)ation of chromatin.
Anachkova, B., Russev, G., & Poirier, G. G. (1989) · PubMed · Cited by 34
PARG deficiency is neither synthetic lethal with BRCA1 nor PTEN deficiency
Noll, A., Illuzzi, G., Amé, J., Dantzer, F., & Schreiber, V. (2016) · Cancer Cell International · doi:10.1186/s12935-016-0333-2 · Cited by 31
Bi, F., Li, D., & Yang, Q. F. (2013) · BioMed Research International · doi:10.1155/2013/946268 · Cited by 28
PARP inhibition — opportunities in pancreatic cancer
Pant, S., Maitra, A., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0257-6 · Cited by 25
PARP inhibition causes premature loss of cohesion in cancer cells
Kukolj, E., Kaufmann, T., Dick, A. E., Zeillinger, R., Gerlich, D. W., & Slade, D. (2017) · Oncotarget · doi:10.18632/oncotarget.21879 · Cited by 23
Self-citationFeng, X., & Koh, D. W. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1740 · Cited by 20
Papeo, G., Avanzi, N. R., Bettoni, S., Leone, A., Paolucci, M., Perego, R., Quartieri, F., Sirtori, F. R., Thieffine, S., Montagnoli, A., et al. (2014) · SLAS DISCOVERY · doi:10.1177/1087057114538319 · Cited by 20
Zhai, L., Li, S., Li, H., Zheng, Y., Lang, R., Fan, Y., Gu, F., Guo, X., Zhang, X., & Fu, L. (2015) · Europe PMC (PubMed Central) · Cited by 20
Cited by
Regulation of SIRT1 and Its Roles in Inflammation
Yang, Y., Liu, Y., Wang, Y., Chao, Y., Zhang, J., Jia, Y., Tie, J., & Hu, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.831168 · Cited by 690
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Dias, M. P., Moser, S. C., Ganesan, S., & Jonkers, J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00532-x · Cited by 505
Molecular Biomarkers in Cancer
Sarhadi, V. K., & Armengol, G. (2022) · Biomolecules · doi:10.3390/biom12081021 · Cited by 467
Role of NAD+ in regulating cellular and metabolic signaling pathways
Amjad, S., Nisar, S., Bhat, A. A., Shah, A. R., Frenneaux, M. P., Fakhro, K., Haris, M., Reddy, R., Patay, Z., Baur, J., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101195 · Cited by 384
DNA Damage/Repair Management in Cancers
Alhmoud, J. F., Woolley, J. F., Al Moustafa, A.-E., & Malki, M. I. (2020) · Cancers · doi:10.3390/cancers12041050 · Cited by 362
Metadata
- Authors
- Slade, D.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2020-02-06
- Volume
- 34
- Issue
- 5-6
- Pages
- 360-394
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W3005496161
- Cited by
- 667
- References
- 337
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.